Skip to main content


DANVILLE, PA -- Adam Buchanan, M.S., M.PH, has been named to the board of directors of the American Board of Genetic Counseling (ABGC).

The ABGC sets standards for certifying genetic counselors and provides leadership in education and promotion surrounding the value of certified genetic counselors. Mr. Buchanan will begin a four-year term with the Board starting in January 2017.

He is an assistant professor at the Genomic Medicine Institute at Geisinger Health System, where he is involved in the program to return important genomic findings to participants in Geisinger’s MyCode Community Health Initiative.  Mr. Buchanan’s research interests include investigating questions about the delivery, follow-up care and support structures needed in large-scale genetic programs.

He is both a licensed and certified genetic counselor. He was previously a research scientist at the Duke Cancer Institute in Durham, N.C. Mr. Buchanan has been an ABGC Diplomate since 2005 and has served as an ABGC Item Writer, developing exam questions. He received his master of science in Genetic Counseling at the University of North Carolina at Greensboro. 


About Geisinger
One of the nation’s most innovative health services organizations, Geisinger serves more than 1.5 million patients in Pennsylvania and New Jersey. The system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. A physician-led organization, with approximately 32,000 employees and more than 1,800 employed physicians, Geisinger leverages an estimated $12.7 billion positive annual impact on the Pennsylvania and New Jersey economies. Repeatedly recognized nationally for integration, quality and service, Geisinger has a long-standing commitment to patient care, medical education, research and community service. For more information, visit, or connect with us on Facebook, Instagram, LinkedIn and Twitter.